I
n research as well as in clinical practice, left ventricular hypertrophy (LVH) is almost universally recognized as one of the most potent markers of cardiovascular (CV) risk. However, the prognostic power of LVH has been substantially tied to a clearcut separation between those who have LVH and those who do not, whereas there is evidence that, like all other biological variables, LV mass follows a normal distribution pattern, and the risk associated with its increase is somewhat continuous. 1, 2 Although it is useful in epidemiology to focus on clearcut CV risk, the "yes/no" separation as regards "good" and "bad" LV mass should be approached with care, especially because it does not allow identification of the "gray areas" that might be very important for CV prevention. Also for classification of arterial hypertension the traditional clearcut separation on the basis of 140/90 mm Hg has being progressively abandoned in both US and European guidelines, [3] [4] [5] because it is clear that the risk associated with blood pressure should be better graded. In 2005, paralleling the trends in the hypertension societies, the inter-society committee of American Society of Echocardiography/ European Society of Cardiology made an important attempt to standardize a classification smoother than the one based on "LVH yes/no". They sought to generate a sex-specific gradation of abnormality (mild, moderate, and severe) for all the parameters used for evaluating LV mass, including raw values and the three most often used indexations for body size: height, height 2.7 , and body surface area (BSA). 6 The committee was excellent in focusing on the need to evolve a better ranking system for evaluation of LV mass, but it did not indicate which parameter(s) among the raw values and the three possible normalizations should be used in clinical practice. In addition, as has been earlier explained, 6 the graded evaluation proposed for LV mass, the various LV mass indices, and other geometric and functional parameters was mainly the result of consultations among experts rather than derived from epidemiological evidence.
In effect, therefore, despite this subtle change in the outlook of the scientific community, the traditional way to deal with CV consequences of hypertension is still to look for the clearcut "presence" or "absence" of LVH.
In this issue of the journal, Cuspidi et al. 7 have highlighted a number of problems emerging from clinical trials, relating to the regression of LVH (i.e., restoration of normal LV mass) or reduction of LV mass (no matter whether associated or not with regression of LVH). Cuspidi et al. 7 focused mainly on two aspects: the confusion existing in literature because of the lack of a standardized definition of LVH, attributed largely to the use of many different cutoff points, and the lack in most clinical trials of clear information about the restoration of normal LV geometry. Both problems have relevance to the challenge of translating the results of clinical trials into clinical practice. Given the widespread attention paid to regression of LVH, the lack of straightforward information on this issue in clinical trials designed for that goal is particularly intriguing.
However, the natural question arising from these observations is: how much information do physicians need about regression of LVH?
At what level of lV mass should we diagnose lVH?
If doctors need a clearcut yes/no classification, LVH should be defined on the basis of the ability to maximize prevention of the CV complications attributable to LVH. In addition to the confusion generated by the use of many different partition values, as highlighted in the Cuspidi study, 7 even more confusion could result from the fact that the method of normalization for body size produces different results in different circumstances. The relative risk of LVH is significant and does not differ, whatever method of normalization for body size is adopted; 8, 9 in contrast the attributable risk in a particular population might be very different depending on the prevalence of obesity. In populations with a high prevalence of obesity, the use of the traditional method of normalizing LV mass for BSA results in an estimate of population attributable risk that is only 50% of the best prediction calculated with LV mass normalized for height raised to the appropriate allometric signal. 9, 10 This difference is offset if the prevalence of obesity in the population is low. 11 Because arterial hypertension is often associated with overweight or obesity, it would be better, in all circumstances, for clearcut classifications of LVH to be based on normalization for height to the allometric signal (2.7 or 2.13), so as to avoid underestimation in the presence of abnormal body size and composition, As clearly highlighted in the report by Cuspidi et al. 7 few studies report the exact rate of regression of LVH, while most trials underline the reduction in LV mass index. Cuspidi et al. 7 implicitly criticize this lack of information. But the real question is: how much do we need this information in a clinical context? As Cuspidi also recognizes, reduction of risk is likely related to reduction in LV mass, and not necessarily to regression of LVH. In addition to the considerations relating to cutoff points and the method of normalization for body size, absolute precision about regression of LVH calls for awareness of each individual's "normal" level, which is almost impossible to predict, especially because the genetic variance of LV mass is relevant. 12 The individual value of LV mass could be actually predicted by considerations of gender, body size (height 2.7 ) and loading conditions, 13 and then compared to the observed value. This estimation of the expected individual value (which does not allow for heritability) explains most of the variance of LV mass. 13 It is potentially useful, 2 but needs further consolidation before it can be accepted for wide clinical application.
Paying more attention to regression of clearcut LVH rather than to the absolute reduction of LV mass index might yield evaluation errors in clinical practice. Echocardiographic estimation of LV mass is operator-dependent and is associated with technical variability; however, it is compatible with practical application in the management of patients. 14 Because LV mass estimation depends on many circumstances including context, regression to the mean, echocardiography laboratory experience, and the patient's general condition, a test-retest variability of 10-18% should always be considered possible when comparing two LV mass values. 14 Therefore a reduction in LV mass index from 64 to 52 g/m 2.7 (i.e., a reduction of ~20% of the initial value) although still in the range of LVH, might be substantially more relevant from a clinical stand-point than a reduction from 53 to 49 g/m 2.7 (i.e., 8%), which is, technically speaking, a regression of LVH, but smaller than the previous example, and biologically meaningless because it falls within the range of the potential technical variability.
Of course, clinical trials should try to complete their information, as Cuspidi pointed out, 7 but in clinical practice some flexibility might be wiser than sticking uncritically to "evidence".
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